Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. Soo RA, Reungwetwattana T, Perroud HA, Batra U, et al. J Thorac Oncol 2024;19:1449-1459.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Soo RA, Reungwetwattana T, Perroud HA, Batra U, et al. Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. J Thorac Oncol 2024;19:1449-1459.
PMID: 38880172